CADL
NASDAQ · Biotechnology
Candel Therapeutics Inc
$4.97
+0.06 (+1.22%)
Financial Highlights (FY 2025)
Revenue
45.25M
Net Income
-4,564,062
Gross Margin
34.4%
Profit Margin
-10.1%
Rev Growth
-8.7%
D/E Ratio
0.84
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 34.4% | 34.4% | 34.4% |
| Operating Margin | -10.5% | -10.5% | -12.7% |
| Profit Margin | -10.1% | -12.1% | -9.8% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.25M | 41.90M | 41.45M |
| Gross Profit | 15.56M | 14.41M | 14.26M |
| Operating Income | -4,738,011 | -4,408,051 | -5,276,771 |
| Net Income | -4,564,062 | -5,052,559 | -4,078,464 |
| Gross Margin | 34.4% | 34.4% | 34.4% |
| Operating Margin | -10.5% | -10.5% | -12.7% |
| Profit Margin | -10.1% | -12.1% | -9.8% |
| Rev Growth | -8.7% | -6.2% | +3.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 147.03M | 131.85M | 164.02M |
| Total Equity | 175.21M | 170.29M | 145.89M |
| D/E Ratio | 0.84 | 0.77 | 1.12 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -6,328,796 | -6,835,485 | -6,691,447 |
| Free Cash Flow | -4,822,512 | -5,572,664 | -3,889,078 |